Novonesis started 2026 with a 7% organic sales growth and a robust adjusted EBITDA margin of 37.8% in Q1, driven by growth across all sales areas and markets. The company confirmed its 2026 outlook with expected organic sales growth of 5-7% and an EBITDA margin between 37-38%. Key highlights include strong performance in Food & Health and Planetary Health Biosolutions, successful bond issuance, and acquisition of a production facility in Thailand to support expansion. Despite global uncertainties, Novonesis remains confident in achieving its long-term growth targets through continued demand for biosolutions.
Ichor Holdings, a semiconductor equipment supply chain company, reported a 24% year-over-year revenue increase to $294.8 million in Q2 2026, driven by recovering demand in semiconductor equipment. The company also improved its non-GAAP gross margin t...
Ethereum has recently surged past $2,500, approaching a technical pattern called a golden cross, where a short-term moving average crosses above a long-term one, often signaling a bullish trend. However, Ethereum's momentum is currently weak, with re...
Bitwise reported about $100 million in net inflows on August 27 across its U.S. crypto exchange-traded products, with Solana funds leading at roughly $40 million, followed by Bitcoin at $22 million and Hyperliquid at $20 million. The Solana Staking E...
MINISO Group reported a 22.4% year-on-year revenue increase to RMB 11.5 billion in the first half of 2026, led by a 26.2% growth in Chinese mainland sales and a 37.0% rise in North America. The company expanded its store network by 769 stores year-ov...
Precious metals prices rose on Friday, lifting shares of London-listed miners Endeavour Mining and Fresnillo on the FTSE 100. Endeavour Mining's stock increased by 2.26% and Fresnillo's by 1.83%, driven by gains in gold, silver, platinum, and palladi...
